Teva posts a discontinuation notice for its generic Saxenda NDC
Teva filed an FDA notice saying it will stop making its five-pen generic Saxenda carton, but a separate FDA database still lists the same product as marketed through September 2027, leaving the practical timeline unclear for patients on liraglutide.
Teva Pharmaceuticals USA filed a discontinuation notice with the FDA on May 14, 2026, saying it will stop manufacturing its generic version of Saxenda, a liraglutide injection sold in a five-pen carton under NDC 0480-7250-46 [1]. The notice appears in the FDA's drug shortages and discontinuations database under the entry for Liraglutide Injection, where the ingredient's overall status is currently listed as "Discontinuation" [1].
The filing itself is sparse. It gives a posting date of May 14, 2026, and a reason of "Discontinuation of the manufacture of the drug," with a company contact number but no stated date for when supply will actually run out [1]. That is a contrast with a separate notice in the same database from Novo Nordisk, the brand-name maker of Saxenda, which posted its own discontinuation notice on August 25, 2026, for its 6 mg/1 mL Saxenda pen (NDC 0169-2800-15) and specified that the product "will be available until discontinuation in January 2027" [1].
Meanwhile, the FDA's separate National Drug Code directory tells a different story for the exact same Teva product. That listing shows the carton, ANDA214568, first went to market on August 28, 2025, and gives a marketing end date of September 30, 2027 — more than a year after Teva's discontinuation posting [2]. The NDC directory record does not explain the gap or say whether that end date will be moved up.
Liraglutide is the active ingredient sold as Saxenda for chronic weight management and as Victoza for type 2 diabetes, both originally made by Novo Nordisk [2]. Teva's generic, cleared as an ANDA, entered the market in 2025 alongside at least one other generic maker, Meitheal Pharmaceuticals, whose liraglutide cartons started shipping in April 2025 [2]. The FDA's underlying openFDA data set that tracks these products was last updated September 11, 2026, and lists 62 total liraglutide-related entries, including bulk ingredient listings not sold to patients [2].
Why it matters for patients
For people currently filling a Teva-brand generic liraglutide prescription, the discontinuation notice is a signal to pay attention, but the FDA's own records do not agree on how soon the product might disappear from pharmacy shelves. The discontinuation posting gives no supply window, while the government's separate drug-listing database still shows the same carton marketed through late September 2027 [1][2]. That inconsistency means pharmacists and patients may not get a clear, single answer from federal sources about exactly when refills could become harder to find.
The notice does not affect Novo Nordisk's brand-name Saxenda, which has its own, later-filed discontinuation notice with a stated cutoff of January 2027, nor does it say anything about Victoza, Ozempic, Wegovy, or Rybelsus, which are separate liraglutide or semaglutide products [1][2]. Patients on other generic liraglutide makers, such as Meitheal, are not mentioned in Teva's notice and are not shown as discontinued in the NDC directory [2].
What happens next
As of the sources reviewed, it is not yet known whether Teva will update its notice with a firm last-shipment date, or whether the NDC directory's September 30, 2027 marketing end date will be revised to match the discontinuation filing [1][2]. Novo Nordisk's brand-name Saxenda is separately set to stop being available in January 2027, according to its own August 2026 filing [1]. Patients and pharmacies watching for updates can check the FDA's shortage database, which is updated as manufacturers file new information [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.